Mycofoli 250 Tablet contains Mycophenolate Sodium 250 mg, a potent immunosuppressant widely used in organ transplant medicine to prevent graft rejection.
This tablet works by inhibiting inosine monophosphate dehydrogenase (IMPDH), thereby suppressing T- and B-lymphocyte proliferation and reducing immune-mediated damage to transplanted organs. It is ideal for patients undergoing renal, cardiac, or hepatic transplant regimens requiring careful immunosuppression under medical supervision.
Clinically, Mycofoli 250 Tablet is used in combination with calcineurin inhibitors and corticosteroids to maintain graft survival and minimize rejection episodes.
The tablet ensures accurate dosing, consistent bioavailability, and reliable therapeutic outcomes, making it suitable for hospitals, transplant centers, specialty pharmacies, and healthcare providers managing post-transplant immunosuppressive therapy.
Common side effects may include gastrointestinal discomfort, nausea, diarrhea, vomiting, headache, and mild infections. Rare but serious effects include severe infections, leukopenia, anemia, thrombocytopenia, or allergic reactions.
Mycofoli 250 Tablet is indicated for the prevention of organ transplant rejection in renal, cardiac, or hepatic transplant recipients. It is also used for the management of certain autoimmune disorders under specialist supervision.
Use Mycofoli 250 Tablet strictly under medical supervision. Regular monitoring of blood counts, liver and kidney function, and infection status is essential. Inform your doctor about any history of infections, bone marrow suppression, or concurrent medications. Avoid live vaccines and contact your physician immediately if persistent fever, unusual bleeding, or severe infections occur.
Store in a cool, dry place below 25°C. Protect from light and moisture. Keep out of reach of children. Do not use beyond the expiry date.